# Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

> **NCT03616184** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 49 (actual)

## Conditions studied

- Graft-versus-host-disease (GVHD)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03616184
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2022-01-22
- **Final completion:** 2023-06-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616184, "Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03616184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*